Submit Deal

NEWLIMIT

Summary

NewLimit is a biotechnology company working to extend human healthspan by developing epigenetic reprogramming therapies.

Deals Overview

Total Deals1

Valued Deals1

Total Value£ 32 M

Avg. Deal Size£ 32 M

Market Context

Senior Management

Sort

Target: NEWLIMIT

Bidder: DIMENSION CAPITAL MANAGEMENT

3 Service Providers

3 Dealmakers

£ 32 M

Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy